{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:27:47Z","timestamp":1774020467607,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jiph.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T12:47:58Z","timestamp":1696510078000},"page":"1942-1946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5353-639X","authenticated-orcid":false,"given":"Chih-Wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ling","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Ta","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Han","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Tsz","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2023.10.007_bib1","unstructured":"World Health Organization, WHO Coronavirus (COVID-19) Dashboard, https:\/\/covid19.who.int\/ [accessed 10 June 2023]."},{"issue":"10","key":"10.1016\/j.jiph.2023.10.007_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"6561","key":"10.1016\/j.jiph.2023.10.007_bib3","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jiph.2023.10.007_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost","volume":"11","author":"Ai","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"10.1016\/j.jiph.2023.10.007_bib5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/v14050961","article-title":"Antiviral Drug Discovery for the Treatment of COVID-19 Infections","volume":"14","author":"Ng","year":"2022","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.jiph.2023.10.007_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M20-8148","article-title":"Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points","volume":"174","author":"Kaka","year":"2021","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jiph.2023.10.007_bib7","doi-asserted-by":"crossref","first-page":"e3996","DOI":"10.1093\/cid\/ciaa1466","article-title":"Compassionate use of remdesivir in pregnant women with severe Coronavirus Disease 2019","volume":"73","author":"Burwick","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.jiph.2023.10.007_bib8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2023.10.007_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.reprotox.2022.01.006","article-title":"Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M(pro) inhibitor in animal models","volume":"108","author":"Catlin","year":"2022","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.jiph.2023.10.007_bib10","unstructured":"National Institutes of Health. Pregnancy, Lactation, and COVID-19 Therapeutics. https:\/\/www.covid19treatmentguidelines.nih.gov\/special-populations\/pregnancy\/pregnancy-lactation-and-covid-19-therapeutics\/; updated April 20, 2023 [accessed 6 June 2023]."},{"key":"10.1016\/j.jiph.2023.10.007_bib11","unstructured":"European Medicines Agency. Paxlovid (PF-07321332\/ritonavir) COVID-19 Article 53 Procedure: Assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-assessment-report_en.pdf; 2021 [accessed 3 June 2023]."},{"key":"10.1016\/j.jiph.2023.10.007_bib12","doi-asserted-by":"crossref","first-page":"m3320","DOI":"10.1136\/bmj.m3320","article-title":"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis","volume":"370","author":"Allotey","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jiph.2023.10.007_bib13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/AOG.0000000000004339","article-title":"Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19","volume":"137","author":"Metz","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jiph.2023.10.007_bib14","article-title":"Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients","author":"Najjar-Debbiny","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2023.10.007_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and Comedications","author":"Marzolini","year":"2022","journal-title":"Clin Pharm Ther"},{"issue":"9","key":"10.1016\/j.jiph.2023.10.007_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jiph.2023.10.007_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/AOG.0000000000004900","article-title":"Short-term pregnancy outcomes after nirmatrelvir\u2013ritonavir treatment for mild-to-moderate Coronavirus Disease 2019 (COVID-19)","volume":"140","author":"Loza","year":"2022","journal-title":"Obstet Gynecol"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123003349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123003349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:22:46Z","timestamp":1761751366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034123003349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1876034123003349"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2023.10.007","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}